Our purpose is to acquire and disseminate new knowledge about lung cancer and how it can be most quickly and effectively diagnosed and treated.
Lung Cancer Frontiers was launched in January 1996 as a newsletter dedicated to advancing knowledge about lung cancer. Its emphasis is on early identification and treatment.
Lung Cancer Frontiers has a renowned international editorial board who is responsible for selecting material for publication. We believe that we have sufficient knowledge today to change the outcome of lung cancer. We can do this with new technologies which were not available at the time of the historic randomized clinical trials on the early diagnosis of lung cancer. These studies were flawed from many standpoints and should not be accepted as dogma today.
Lung Cancer Frontiers has been sent to all board certified pulmonologists in North America. We must get pulmonologists involved in the new era where lung cancer can be found, treated and cured. Pulmonologists can and must play a central role in the diagnosis and treatment of lung cancer.
We will only cite reports from the peer reviewed literature and will feature abstracts from journals that may not be read regularly by pulmonologists. Editorial comments will accompany most citations. Lung Cancer Frontiers will also cover highlights of selected symposia, on lung cancer in order to bring timely new information to our readership. We hope to expand our circulation to include oncologists, radiologists and surgeons in the future. Multimodality approaches to treatment and diagnosis of lung cancer are needed in the new millennium as we begin to explore how to change the socioeconomic impact of the most common fatal malignancy of both men and women. We can make a difference.
—TLP for the Editorial Board.
|